Gennova Gets DCGI Nod For Phase 2, 3 Trials Of Its MRNA COVID Vaccine

[email protected]13 Oct, 2021News

India's first mRNA-based Covid-19 vaccine candidate HGCO19 by Gennova Biopharmaceuticals Ltd has been granted approval for phase 2/3 clinical trials, the department of biotechnology (DBT) said on Tuesday. The Pune-based biotechnology company had submitted the interim clinical data of the vaccine's phase 1 study to the central drugs standard control organisation, it said.The vaccine subject expert committee reviewed the interim phase 1 data and found that the HGCO19 vaccine was safe, tolerable, and immunogenic in the participants of the study.